- Report
- October 2024
- 188 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2022
- 112 Pages
Global
From €2614EUR$2,750USD£2,196GBP
€5229EUR$5,500USD£4,393GBP
- Report
- October 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2022
- 111 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- July 2024
- 88 Pages
Global
From €3500EUR$3,944USD£3,043GBP
The DNA Repair Drug market is a subset of the genomics industry that focuses on the development of drugs that can repair damaged DNA. These drugs are used to treat a variety of genetic diseases, including cancer, and can be used to prevent the onset of certain diseases. DNA repair drugs are typically administered through a variety of methods, including intravenous, oral, and topical applications.
The DNA Repair Drug market is highly competitive, with a number of companies vying for market share. Companies in the market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new drugs to treat genetic diseases, as well as exploring new methods of delivery. Additionally, many of these companies are investing in research and development to create more effective treatments for genetic diseases. Show Less Read more
